Clin2
NCT07549516Worth exploringRecruiting

Asciminib for Philadelphia chromosome-positive CML in chronic phase

Leukemia, Chronic Myeloid

Part of Blood & lymphatic, Cancer clinical trials.

This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
380 people
Ages
18 years to 100 years
Study type
Observational

Who can take part

  • Aged 18 years or older.
  • Diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
  • Either newly diagnosed OR have tried only one previous TKI treatment (if choosing asciminib).
  • Not planning to take other investigational drugs during the study.
  • Willing and able to complete questionnaires about how you feel and complete follow-up visits.
  • Able to provide written informed consent.
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel
  • fitModel

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07354074Recruiting· Phase 2
Study of asciminib for children with Ph+ CML

This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.

New Brunswick, New Jersey
NCT06236724Recruiting· Phase 2
Asciminib for newly diagnosed chronic myeloid leukemia

This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.

Houston, Texas
NCT04877522Recruiting· Phase 4
Continued asciminib treatment for certain leukemia patients

This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.

Ann Arbor, Michigan
NCT06409936Recruiting· Phase 2
Early use of asciminib for new CML patients

This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.

Barcelona
NCT07681258Not yet recruiting
Asciminib safety study for young adults with CML in the Gulf region

This study looks at the safety and effects of the drug asciminib in young adults (18 and older) with a type of leukemia called chronic myeloid leukemia (CML). It uses information already collected from patients' medical records to see how well the drug works and how safe it is.

NCT06629584Recruiting· Phase 2
Asciminib for second-line chronic phase CML

This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.

Houston, Texas

Hear when a new Leukemia, Chronic Myeloid trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.